Pressemeldinger

Bristol-Myers Squibb får positiv CHMP-vurdering for Daklinza® (daclatasvir) for behandling av kronisk hepatitt C i EU

30-06-2014 14:00 CEST Bristol-Myers Squibb

Nye muligheter ved tilbakefall av myelomatose

30-06-2014 13:25 CEST Novartis Onkologi Tilleggsbehandling med panobinostat forlenger progresjonsfri overlevelse med hele 37%, viser nye studier.

BIOGEN IDEC AND ABBVIE ANNOUNCE POSITIVE TOP-LINE RESULTS FROM PHASE 3 STUDY INVESTIGATING DACLIZUMAB HIGH-YIELD PROCESS IN MULTIPLE SCLEROSIS

17-06-2014 13:58 CEST Biogen Idec Norway AS − DAC HYP Demonstrated Superiority Over Interferon Beta-1a in Annualized Relapse Rate – − Positive Results Set Stage for Regulatory Filings –

02-06-2014 14:00 CEST Bristol-Myers Squibb

Apotek 1 åpner sitt apotek nummer 300!

02-06-2014 07:05 CEST Apotek 1 Landets største apotekkjede åpner 2.juni Apotek 1 Elverum. Det blir kjedens apotek nummer 300. Da apotekmonopolet ble opphevet med ny apoteklov i 2001 var det 397 apotek. Medregnet Apotek 1 Elverum teller dagens apotek 774. –Dette er en utvikling som kommer kundene til gode, sier administrerende direktør i Apotek 1 Øyvind Winther.

BIOGEN IDEC ANNOUNCES OFFICIAL PARTNERSHIP WITH SAILING SCLEROSIS’ “OCEANS OF HOPE” TO GLOBALLY CHANGE PERCEPTIONS OF MS

28-05-2014 10:51 CEST Biogen Idec Norway AS - Global Project Uses Sailing to Empower People Living with Multiple Sclerosis -

CHMP ADOPTS POSITIVE OPINION FOR PLEGRIDYTM (PEGINTERFERON BETA-1A) AS A TREATMENT FOR MULTIPLE SCLEROSIS IN THE EUROPEAN UNION

28-05-2014 10:41 CEST Biogen Idec Norway AS – European Commission Decision on Marketing Authorization Anticipated in 2H of 2014 – – PLEGRIDY May Offer People with MS a Combination of Efficacy, Favorable Safety Profile and Low Frequency Dosing Schedule –

For første gang i Norge: Nå kommer smertestillende for halsen

21-05-2014 09:08 CEST Meda AS For første gang i Norge lanseres nå en smertestillende tablett for halsen. Den heter Zyx, er en sukkerfri sugetablett med sitron- eller mintsmak, og lokalbedøvende og betennelsesdempende effekt. Slik skal nordmenns vonde halser få rask lindring.

 In Phase 2 and 1b Renal Cell Carcinoma Trials, Investigational PD-1 Immune Checkpoint Inhibitor Nivolumab Showed Antitumor Activity as a Single Agent and in Combination Regimen with Yervoy® (ipilimumab)

16-05-2014 10:17 CEST Bristol-Myers Squibb

Investigational PD-1 Immune Checkpoint Inhibitor Nivolumab Showed Antitumor Activity in Previously Treated and Chemotherapy-Naïve Patients in Phase 1b                                             Non-Small Cell Lung Cancer Trials

16-05-2014 10:13 CEST Bristol-Myers Squibb